GSD Share Price Performance
CA$0.17
0.02 (9.68%)
Price CA$0.17
Share PriceCA$0.17
The Market Lifts Devonian Health Group Inc. (CVE:GSD) Shares 31% But It Can Do More
Sep 11
Devonian Health Group Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
GSD Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
Devonian Health Group Inc. Key Details
About GSD
- Founded
- n/a
- Employees
- 7
- CEO
- WebsiteView website
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis. The company also develops Pantoprazole Magnesium for the treatment of gastric reflux; Cleo-35 for the treatment of hormonal acne in women; Dexlansoprazole; R-Spinasome anti-aging cream, serum, and regenerating creams; and anti-aging products, including day, night, and eye creams under the Purgenesis name. Devonian Health Group Inc. is headquartered in Québec, Canada.
